Since most cases of PsoDermatitis are drug-related (such as anti-TNF-α, anti-IL-4/12/13/17/23), as will be explained later, the introduction of biologics for the treatment of Pso (Etanercept, which was FDA-approved in April 2004) and AD (Dupilumab, which was FDA-approved in March 2017) has undoubtedly contributed to the substantial increase in the number of reported cases. This evidence concerns the gene TNF and Alzheimer disease.